nach oben

Journal of General Internal Medicine

Erschienen in:

24.07.2019 | Editorial

The HCV Treatment Cascade: Race Is a Factor to Consider

verfasst von: Maya Balakrishnan, MD, MPH, Fasiha Kanwal, MD, MSHS

Erschienen in: Journal of General Internal Medicine | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Excerpt

Chronic hepatitis C is the most common blood-borne viral infection in the USA and a leading cause of chronic liver disease, liver failure, and hepatocellular carcinoma (HCC). The complications of HCV infection are preventable. Antiviral treatment with sustained virological response (SVR) is associated with a 71–76% reduction in HCC risk¹ and a 74% reduction in risk of death compared to ongoing active infection.² …

Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153(4):996–1005.e1.CrossRef

Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology (Baltimore, Md). 2017.

Yehia BR, Schranz AJ, Umscheid CA, Lo Re V, 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PloS One. 2014;9(7):e101554.CrossRef

Brady JE, Vellozzi C, Hariri S, Kruger DL, Nerenz DR, Brown KA, et al. Hepatitis C care cascade among persons born 1945-1965: 3 medical centers. Am J Manag Care. 2018;24(9):421–7.

Kim NJ, Locke CJ, Park H, Magee C, Bacchetti P, Khalili M. Race and Hepatitis C Care Continuum in an Underserved Birth Cohort. J Gen Intern Med. https://doi.org/10.1007/s11606-018-4649-6.CrossRef

Kasting ML, Giuliano AR, Reich RR, Roetzheim RG, Nelson DR, Shenkman E, et al. Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2018;27(4):503–13.

Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis c antibody in u.s. primary care settings. Ann Intern Med. 2012;156(4):263–70.CrossRef

Lin M, Kramer J, White D, Cao Y, Tavakoli-Tabasi S, Madu S, et al. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017;46(10):992–1000.CrossRef

Nili M, Luo L, Feng X, Chang J, Tan X. Disparities in hepatitis C virus infection screening among Baby Boomers in the United States. Am J Infect Control. 2018;46(12):1341–7.CrossRef

10.

Backus LI, Belperio PS, Loomis TP, Mole LA. Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health. 2014;104 Suppl 4:S555–61.CrossRef

11.

Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, et al. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther. 2018;47(7):1023–31.CrossRef

12.

Turner BJ, Wang CP, Melhado TV, Bobadilla R, Jain MK, Singal AG. Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared with Other Ethnic Groups. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018.

13.

El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014;109(9):1427–35.CrossRef

14.

Eckman MH, Ward JW, Sherman KE. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018.

Titel: The HCV Treatment Cascade: Race Is a Factor to Consider
verfasst von: Maya Balakrishnan, MD, MPH
Fasiha Kanwal, MD, MSHS
Publikationsdatum: 24.07.2019
Verlag: Springer International Publishing
Erschienen in: Journal of General Internal Medicine / Ausgabe 10/2019
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-019-04962-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

17.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The HCV Treatment Cascade: Race Is a Factor to Consider

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

What Care Models Have Generalists Implemented to Address Transition from Pediatric to Adult Care?: a Qualitative Study

Physicians Interrupting Patients

Early Health System Experiences with Collaborative Care (CoCM) Billing Codes: a Qualitative Study of Leadership and Support Staff

Menopausal Symptoms and Higher Risk Opioid Prescribing in a National Sample of Women Veterans with Chronic Pain

Education Indicators for Internal Medicine Point-of-Care Ultrasound: a Consensus Report from the Canadian Internal Medicine Ultrasound (CIMUS) Group

Patterns of Breast Imaging Use Among Women with a Personal History of Breast Cancer

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin